Programmed cell death or apoptosis of infected host cells is an important defense mechanism in response to viral infections. This process is regulated by proapoptotic and prosurvival members of the B-cell lymphoma 2 (Bcl-2) protein family. To counter premature death of a virus-infected cell, poxviruses use a range of different molecular strategies including the mimicry of prosurvival Bcl-2 proteins. One such viral prosurvival protein is the fowlpox virus protein FPV039, which is a potent apoptosis inhibitor, but the precise molecular mechanism by which FPV039 inhibits apoptosis is unknown. To understand how fowlpox virus inhibits apoptosis, we examined FPV039 using isothermal titration calorimetry, small-angle X-ray scattering, and X-ray crystallography. Here, we report that the fowlpox virus prosurvival protein FPV039 promiscuously binds to cellular proapoptotic Bcl-2 and engages all major proapoptotic Bcl-2 proteins. Unlike other identified viral Bcl-2 proteins to date, FPV039 engaged with cellular proapoptotic Bcl-2 with affinities comparable with those of Bcl-2's endogenous cellular counterparts. Structural studies revealed that FPV039 adopts the conserved Bcl-2 fold observed in cellular prosurvival Bcl-2 proteins and closely mimics the structure of the prosurvival Bcl-2 family protein Mcl-1. Our findings suggest that FPV039 is a pan-Bcl-2 protein inhibitor that can engage all host BH3-only proteins, as well as Bcl-2-associated X, apoptosis regulator (Bax) and Bcl-2 antagonist/killer (Bak) proteins to inhibit premature apoptosis of an infected host cell. This work therefore provides a mechanistic platform to better understand FPV039-mediated apoptosis inhibition.

Programmed cell death or apoptosis is a highly organized and tightly regulated mechanism of cell suicide (1, 2) and is evolutionary conserved in all multicellular organisms (3). Apoptosis allows the removal of impaired, unwanted, or diseased cells (4). In addition to organogenesis, homeostasis, and roles in development, apoptosis also acts as a host defense mechanism to remove infected cells during viral infection, thus preventing viral survival and proliferation (5).

B-cell lymphoma 2 (Bcl-2)³ proteins are the main regulators of apoptosis executed by the intrinsic pathway (2). The Bcl-2 protein family is divided into two subfamilies, the proapoptotic Bcl-2 and prosurvival Bcl-2 proteins (6), which are characterized by the presence of one or more of the four conserved Bcl-2 homology (BH) motifs (7). Proapoptotic Bcl-2 proteins are further subdivided into members that contain multiple BH domains including Bax and Bak and the BH3-only proteins, which only harbor a BH3 motif. Upon activation, proapoptotic Bak and Bax oligomerize to permeabilize the outer mitochondrial membrane (8), leading to the release of apoptogenic mediators such as cytochrome c that ultimately activate caspases and lead to the destruction of the cell (4). Bak and Bax are activated by the expression of proapoptotic BH3-only proteins including Bim, Bid, Noxa, and Puma, which are able to directly bind and activate Bak and Bax, or by neutralizing prosurvival Bcl-2 protein such as Bcl-2, Mcl-1, Bcl-xL, A1, Bcl-w, and Bcl-b (9). Structural studies have shown that the three subfamilies interact with each other in a BH3 motif-dependent manner where the BH3 motif of a proapoptotic protein will interact with an extended hydrophobic groove in a receiving prosurvival Bcl-2 protein (10).

Premature host cell apoptosis plays a significant role in combating viral infections, and many viruses have evolved strategies to counter host cell apoptotic defenses (5). For instance, many viruses express prosurvival factors to extend the lifespan of infected host cells (11). Numerous large DNA viruses utilize sequence and/or structural mimics of prosurvival Bcl-2 to inhibit apoptosis (7). Examples include γ-herpesviruses 68 M11 (12), adenovirus E1B19K (13), and African swine fever virus A179L (14). Among the poxviruses, a number of homologs of Bcl-2 have been identified including M11L from myxoma virus (15), F1L from vaccinia virus (16, 17) and variola virus (18), sheeppox virus SPPV14 (19), and deerpox virus DPV022 (20, 21). Interestingly, structural studies showed that M11L, F1L,
and DPV022 adopt a Bcl-2 fold despite a lack of detectable sequence similarity to Bcl-2 (21–25). Functionally, M11L was shown to act by sequestering Bak and Bak (24), whereas F1L inhibits apoptosis by sequestering Bim (22).

Sequencing of the fowlpox virus genome and subsequent analysis identified the virus open reading frame 39 (FPV039) (26) as a putative prosurvival Bcl-2 protein due to the presence of recognizable BH1 and BH2 motifs as well as a C-terminal transmembrane domain (27). Subsequent studies revealed that FPV039 is a potent inhibitor of apoptosis and localizes to the mitochondrial membrane via a C-terminal transmembrane domain. Mechanistically, FPV039 suppresses apoptosis triggered by overexpression of proapoptotic proteins including Bak and Bax and all the BH3-only proteins and was shown to immunoprecipitate with the BH3-only proteins Bim and Bik as well as Bak and activated Bax (27, 28). However, the precise molecular and structural basis of how FPV039 inhibits apoptosis remains to be determined. To address these questions, we investigated the binding of FPV039 to peptides encoding the BH3 domain from all proapoptotic Bcl-2 family members including Bak, Bax, and Bok and all the BH3-only proteins. We then determined crystal structures of FPV039 bound to two of the identified interactors, Bmf and Bik BH3. Our studies showed that FPV039 is a highly promiscuous prosurvival viral Bcl-2 (vBcl-2) protein that binds to all BH3-only proteins as well as Bax and Bak and provide a mechanistic platform to understand FPV039-mediated apoptosis inhibition.

**Results**

To understand how FPV039 interacts with proapoptotic members of the Bcl-2 family of proteins, truncated FPV039 comprising the first 143 residues was recombinantly expressed in *Escherichia coli* and purified using a two-step purification method using affinity chromatography followed by size-exclusion chromatography. FPV039 exhibited low solubility, necessitating sample buffer optimization to achieve concentrations of 30 μM in a final buffer comprising 20 mM trisodium citrate, pH 6.0, 200 mM sodium chloride. We then examined binding of FPV039 to peptides encompassing the BH3 domain of all proapoptotic Bcl-2 proteins using isothermal titration calorimetry (ITC). Unexpectedly, ITC revealed that FPV039 was able to bind to peptides of all BH3-only proteins as well as peptides from Bak and Bax but not Bok (Fig. 1). FPV039 engages several BH3-only proteins with high affinity including Bid (2 nM), Bim (15 nM), Hrk (24 nM), Bmf (16 nM), Puma (24 nM), Noxa (28 nM), and Bik (30 nM). In contrast, FPV039 only engaged Bad (653 nM) with moderate affinity. Furthermore, FPV039 bound Bak BH3 with 76 nM affinity and Bax BH3 with 40 nM affinity.

Because several viral prosurvival proteins from the Poxviridae have been shown to form dimers (18, 21, 23, 29), we next investigated the oligomeric state of FPV039 using small angle X-ray scattering (SAXS) (Table 1). In the presence of BH3 domain peptides, FPV039 could be concentrated to higher concentration, allowing us to perform SAXS analysis of FPV039-Bak BH3 domain peptide complex at concentrations ranging from 0.31 to 7.35 mg/ml. The scattering curve profile is conserved throughout the concentration range tested, suggesting an absence of interparticle interference (Fig. 2). The scattering conforms to a straight line in the low q region on the Guinier plot (Fig. 2A), and the calculated radius of gyration does not vary significantly with the measured concentration range, suggesting an absence of significant concentration effects from the highest concentration (Fig. 2). The molecular mass calculated from I(0) on the absolute scattering scale across the concentration range was ~20.0 kDa, corresponding to an oligomerization state of ~1 for the FPV039-Bak BH3 domain complex (Fig. 2C).

To understand the structural basis of FPV039 interaction with the BH3 domain of proapoptotic Bcl-2 proteins, we determined the structures of FPV039 in complex with Bmf (Fig. 3A and Table 2) and Bik BH3 domains (Fig. 3B). Although FPV039 has limited sequence identity to Bcl-2 proteins, FPV039 adopts a Bcl-2 fold comprising eight α-helices and harboring the conserved BH3 domain-binding groove observed in all the other prosurvival Bcl-2 members that is used to bind both Bmf and Bik BH3 domains (Fig. 4, A and B). Interestingly, FPV039 features an extended loop between α5 and α6 that is only visible in the FPV039-Bik BH3 complex structure but not in the FPV039-Bmf BH3 complex structure, suggesting considerable flexibility in the loop. The closest structural homolog as identified by a Dali search is Mcl-1 (root mean square deviation of 0.92 Å over 107 Ca carbon atoms with 25% sequence identity), whereas BHRF1 is the closest vBcl-2 homolog (30).

FPV039 engages the BH3 domain of proapoptotic Bcl-2 proteins using the canonical ligand-binding groove found in other prosurvival Bcl-2 proteins. The ligand-binding groove of FPV039 is formed by α2–α5 with the α5 helix forming the floor of the groove. FPV039 bound to the BH3 domains of Bmf and Bik by utilizing the four conserved hydrophobic residues in the BH3 domain as well as a conserved ionic interaction between Asp-57 (for Bmf) and Asp-57 (for Bik) from the BH3 domain and Arg-85 from FPV039 (Figs. 4, C and D, and 5A).

Inspection of the FPV039-Bmf BH3 complex interface (Fig. 4C) revealed that Bmf residues Ile-142, Leu-146, Ile-149, and Phe-153 protrude into four hydrophobic pockets on the FPV039-binding groove. Furthermore, four hydrogen bonds and a salt bridge are found at the interface with the salt bridge formed by Arg-85(FPV039)–Asp-151(Bmf), and the hydrogen bonds are formed by Tyr-141(FPV039) and His-154(Bmf), Asn-82(FPV039) and Asp-151(Bmf), Asp-79(FPV039) and Gln-147(Bmf), and Arg-65(FPV039) and Thr-138(Bmf).

Similarly, the interface of FPV039 and the Bik BH3 domain (Fig. 4D) involves four hydrophobic residues of Bik (Phe-60, Ile-56, Leu-53, and Val-49), which protrude into four hydrophobic pockets on FPV039. Furthermore, the salt bridge observed in FPV039-Bmf is conserved and formed by Arg-85(FPV039)–Asp-57(Bik) in the FPV039-Bik BH3 domain complex. A total of five hydrogen bonds are formed between Bik BH3 domain and FPV039, two of which are also observed in FPV039-Bmf including Tyr-141(FPV039)–Asn-61(Bik) and Asn-82(FPV039)–Asp-57(Bik). In contrast, three of the hydrogen bonds are unique to FPV039-Bik and not found in the Bmf complex, and these are formed by Ser-50(FPV039)–Tyr-64(Bik), Lys-80(FPV039)–Asp-57(Bik), and Gln-75(FPV039)–Gln-48(Bik).
Discussion

Numerous viruses have been shown to express proteins to specifically inhibit apoptosis (5, 7), in particular the Bcl-2-mediated pathway, to ensure viral survival and proliferation. Some of these viral effector proteins harbor detectable sequence identity to members of the Bcl-2 family of proteins (7). Recognizable Bcl-2 mimics encoded by viruses include adenovirus E1B19K (13), Kaposi sarcoma herpesvirus KsBcl-2 (31), Epstein-Barr
virus BHRF1 (32), γ-herpesvirus 68 M11 (12), African swine fever virus A179L (14, 33), turkey herpesvirus vNR13 (34), and orf virus ORFV125 (35) as well as the poxviral Bcl-2 proteins SPPV14 from sheeppox (19) and CNP058 from canarypox virus (36). However, many other virulence factors, in particular from poxviruses, share very limited sequence identity to prosurvival Bcl-2 but retain the Bcl-2 fold. Examples of such virulence factors include deerpox virus DPV022 (20, 21), vaccinia virus (22, 23) and variola virus F1L (18), and myxoma virus M11L (24).

Table 1
Small-angle X-ray scattering data collection and scattering-derived parameters

| FPV039-Bak | BH3 domain |
|------------|------------|
| Data collection parameters | |
| Instrument | SAXS/WAXS beamline, Australian Synchrotron |
| Beam geometry (μm) | 80 × 200 |
| Wavelength (keV) | 12 |
| q range (Å⁻¹) | 0.011–0.619 |
| Exposure time (s) | 1 (per frame; 17 frames) |
| Concentration range (mg ml⁻¹) | 0.31–7.35 |
| Temperature (K) | 293.15 |
| Structural parameters | |
| I₀ (from Guinier) (cm⁻¹) | 0.10 ± 0.000 |
| Rg (from Guinier) (Å) | 19.66 ± 0.06 |
| Molecular mass determination | |
| Partial specific volume (cm³ g⁻¹) | 0.737 |
| Contrast (Δρ × 10¹⁰ cm⁻²) | 2.900 |
| Mₘ (from I₀) (Da) | 17,902 |
| Calculated monomeric M, from sequence (Da) | 20,022 |
| Software used | |
| Primary data reduction | SAXS/WAXS beamline software |
| Data processing | PRIMUS |

* Reported for 7.35 mg/ml.
* Determined with MULCh (74).

Figure 2. FPV039 is a monomer in solution. A, log plot of FPV039(1–143) raw SAXS data. Concentrations are in decreasing order starting at 7.35 mg/ml (top) followed by 3.34, 1.56, 0.70, and 0.31 mg/ml. B, Guinier plots of FPV039 SAXS data. Concentrations are as in A, C, summary of the SAXS data and analysis of the oligomeric state of FPV039 in solution.

FPV039 was identified as a putative vBcl-2 in the fowlpox virus genome as it shares limited sequence identity with mammalian Bcl-2 proteins (26). Cellular studies showed that FPV039 is a potent apoptosis inhibitor where FPV039 was able to inhibit apoptosis induced by Bak and Bax as well as all the BH3-only proteins (27, 28). However, the molecular basis of apoptosis inhibition remained unclear. To address this, we examined the ability of FPV039 to bind to BH3 domains of all proapoptotic Bcl-2 members (Figs. 1 and 5B). FPV039 exhibited binding to peptides of all BH3-only proteins with low nanomolar affinities except for Bad, which was only bound with modest affinity (653 nM). Furthermore, FPV039 bound the BH3 domain of the proapoptotic executor protein Bak with 76 nM affinity and Bax BH3 with 76 nM affinity but did not exhibit binding to Bok BH3. These findings suggest that FPV039 is able to neutralize all key Bcl-2-mediated aspects of the intrinsic apoptosis pathway by preventing initiation of apoptosis by directly sequestering all BH3-only proteins while also engaging proapoptotic Bak and Bax. Interestingly, Banadyga et al. (28) previously determined that FPV039 is only able to immunoprecipitate the BH3-only proteins Bim and Bik as well as proapoptotic Bak and activated Bax. Although this report also revealed some evidence for additional interactions with Noxa, Bid, and Bmf, ultimately the authors concluded that there was insufficient evidence for an interaction. We have now shown biochemically that peptides spanning the BH3 domain from all BH3-only proteins are able to engage FPV039. This discrepancy could be due to the use of peptides rather than full-length proteins, although we note that it has been previously shown that the isolated BH3 domain of BH3-only proteins recapitulates the bulk of the properties of their full-length counterparts (37). Considering
the tight nanomolar affinity of FPV039 for some of the BH3-only proteins that were not observed to immunoprecipitate, this discrepancy is surprising. However, this issue is compounded by the observation that immunoprecipitation experiments for Bcl-2 protein interactions are influenced by the choice of detergent (38), and ultimately a different choice of detergent for the immunoprecipitation experiment may have yielded a different outcome.

At the structural level, FPV039 displays certain features that are unusual in the wider Bcl-2 family. Long loop regions are typically located in the loop connecting \( \alpha_9 \) and \( \alpha_10 \) such as in Bcl-2 and Bcl-xL, which both feature particularly long connecting loops. In contrast, FPV039 contains a long loop connecting \( \alpha_5 \) and \( \alpha_6 \), a feature only previously seen in Bcl-b and its mouse homolog Boo. However, despite the topological similarity to Bcl-b and Boo, FPV039 is highly promiscuous with respect to binding proapoptotic Bcl-2 proteins, whereas Bcl-b only binds Bim and Bax (39). For Boo, conflicting interaction studies have been published, suggesting that Boo is either unable to bind proapoptotic Bcl-2 family members (40) or engages all of them with weak micro- or millimolar affinities (41).

Among the vBcl-2 proteins, only BHRF1 displays a long connecting sequence, which is located between \( \alpha_1 \) and \( \alpha_2 \) and harbors a short additional helical sequence (30), with the remaining structures of vBcl-2 proteins displaying compact helical bundle folds with very short loops. In the cases of vaccinia and variola virus F1L (18, 22) and deerpox virus DPV022 (21), the

---

**Table 2**

Data collection and refinement statistics

|                      | FPV039-Bmf BH3 | FPV039-Bik BH3 |
|----------------------|---------------|---------------|
| **Data collection**   |               |               |
| Space group          | C2            | P4_1          |
| No. of molecules in  | 2 + 2         | 1 + 1         |
| asymmetric unit      |               |               |
| Cell dimensions      |               |               |
| \( a, b, c \) (Å)    | 123.60, 41.20, 67.82 | 47.85, 47.85, 74.30 |
| \( \alpha, \beta, \gamma \) (\(^\circ\)) | 90.00, 93.14, 90.00 | 90.00, 90.00, 90.00 |
| Wavelength (Å)       | 0.9537        | 0.9537        |
| Resolution (Å)       | 46.91–1.65 (1.68–1.65) | 47.85–1.35 (1.37–1.35) |
| No. unique reflections | 40,990 (1971) | 36,750 (1846) |
| \( R_{	ext{sym}} \)  | 0.050 (1.087) | 0.070 (1.592) |
| \( I/\sigma(I) \)    | 10.7 (1.1)    | 25.79 (1.7)   |
| CC1/2                | 0.99 (0.68)   | 1.00 (0.60)   |
| Wilson B-factor      | 25.6          | 13.8          |
| Completeness (%)     | 99.9 (98.6)   | 100 (100)     |
| Redundancy           | 3.9 (3.9)     | 14.5 (13.5)   |

| **Refinement**       |               |               |
| Resolution (Å)       | 1.65          | 1.35          |
| No. reflections      | 40,942        | 36,707        |
| \( R_{	ext{sym}}/R_{	ext{merge}} \) | 0.1729/0.2067 | 0.1444/0.1716 |
| No. atoms            |               |               |
| Protein              | 2,601         | 1,348         |
| Ligand/ion           | 6             | 13            |
| Water                | 298           | 202           |
| B-factors            |               |               |
| Protein              | 39.13         | 16.35         |
| Ligand/ion           | 57.95         | 24.53         |
| Water                | 46.53         | 29.94         |
| r.m.s. deviations    |               |               |
| Bond lengths (Å)     | 0.007         | 0.008         |
| Bond angles (\(^\circ\)) | 0.77      | 0.87          |
| Ramachandran statistics (%) |         |               |
| Favored              | 96.26         | 98.08         |
| Allowed              | 3.74          | 1.92          |
| Disallowed           | 0.00          | 0.00          |

---

**Figure 3.** 2\( F_o \) – \( F_c \) electron density maps of FPV039-BH3 domain complexes. A, electron density map encompassing the hydrophobic binding groove of FPV039 in complex with Bmf BH3. FPV039 is shown as cyan sticks, and Bmf BH3 is shown as green sticks. The electron density map is shown as a blue mesh contoured at 2\( \sigma \). B, electron density map encompassing the hydrophobic binding groove of FPV039 in complex with Bik BH3. Molecules are shown as in A except for Bik BH3, which is shown as pink sticks.
loop connecting α1 and α2 is particularly short, resulting in a dimeric domain-swapped arrangement.

Although a number of structures of prosurvival Bcl-2 proteins bound to BH3-only proteins have been determined, the structural bases of prosurvival Bcl-2 protein interactions with Bik and Bmf are not well characterized. To date, no other structures of prosurvival Bcl-2 proteins with Bik have been solved, and the only complex structure involving Bmf that has been determined is the A1-Bmf BH3 complex (Fig. 4E). Interestingly, A1 binding to Bmf BH3 does not involve the hallmark ionic interaction between the conserved arginine from the NWGR sequence with the conserved aspartic acid from the BH3 domain that is observed in the FPV039-Bmf complex (42). Furthermore, the numerous additional hydrogen bond interactions seen in FPV039-Bmf complex are also absent in A1-Bmf complex (Fig. 4E) including interactions contributed by FPV039 Asp-79, Asn-82, and Arg-85, which are conserved between FPV039 and A1. Consistent with this, FPV039 engages Bmf with a higher affinity compared with A1 (17 and 160 nM, respectively) (42). In contrast, Mcl-1 utilizes the same interactions to bind Bax as FPV039 (Fig. 4F), consistent with the identification of Mcl-1 as the closest structural homolog of FPV039.

Our findings that FPV039 is able to bind to all BH3-only proteins as well as Bak and Bax has implications for the putative mechanism of apoptosis inhibition. The major cellular prosurvival Bcl-2 proteins Bcl-2, Bcl-xL, Bcl-w, Mcl-1, and A1 harbor distinct binding profiles for proapoptotic Bcl-2 proteins as shown by their ability to bind either the BH3-only protein Bad or Noxa. These overlapping but distinct binding profiles enable finely tuned and differential regulation of apoptosis in a cell (43). Interestingly, the binding profile for FPV039 for proapoptotic Bcl-2 proteins differs from its cellular counterparts in two significant aspects. FPV039 is able to engage both Bad and Noxa with measurable affinity, which is highly unusual among prosurvival Bcl-2 proteins (Table 3). In particular, the high-affinity interaction with Noxa BH3 domain is striking. This feature is unique to FPV039. Although orf virus ORFV125 has been shown to engage Noxa by immunoprecipitation, the affinity for this interaction has never been determined (44). The only other Noxa-binding vBcl-2 protein is A179L, which displays only moderate affinity (33). Noxa has been shown to be a crucial contributor in defense mechanisms during viral infection where Noxa expression greatly increased in the cells exposed to double-stranded RNA, interferon (IFN), and virus (45, 46). The high-affinity interaction of FPV039 with Noxa that we found suggests that fowlpox virus is able to counter host defense mechanisms initiated via Noxa during viral infection. Furthermore, our data suggest that FPV039 is capable of preventing initiation of Bcl-2-mediated apoptosis by directly sequestering all BH3-only proteins while also engaging the proapoptotic executor proteins Bak and Bax to prevent perforation of the outer mitochondrial membrane.
quently, FPV039 is in principle equipped to neutralize a vast range of apoptotic stimuli and constitutes a broad spectrum Bcl-2 inhibitor.

A number of studies on virus-encoded Bcl-2 proteins revealed that the range of proapoptotic Bcl-2 proteins that they interact with varies considerably across the different proteins and that a number of molecular mechanisms of action are utilized to inhibit premature host cell apoptosis (7, 21, 47). vBcl-2 members have been demonstrated to rely either on sequestration of Bax and Bak as shown for myxoma virus M11L (24), sequestration of Bim as shown for vaccinia virus F1L (22), or a mixed mode reliant on neutralization of both Bim and Bak as

![Figure 5. Sequence alignments of FPV039 with Bcl-2 family members.](image)

**Table 3**

| Poxviral Bcl-2 | Asfarviridae Bcl-2 | Herpesviral Bcl-2 | Cellular Bcl-2 |
|----------------|--------------------|------------------|----------------|
| SPPV14 | MvAFL1 | DPV022 | FPV039 |
| **Bad** | >2,000 | >1,000 | NB | 653 | 258 | >2,000 | >1,000 | n/a | 16 | 30 | 5.3 | >100,000 | 15,000 |
| **Bid** | 341 | 100 | NB | 2 | 26 | 109 | 112 | 232 | 6,800 | 40 | 82 | 2,100 | 1 |
| **Bik** | >2,000 | >1,000 | NB | 30 | 190 | >2,000 | >1,000 | n/a | 850 | 12 | 43 | 1,700 | 58 |
| **Bim** | 26 | 5 | 250 | 140 | 10 | 6 | 18 | 29 | 131 | 2.6 | 4.3 | 4.6 | 2.4 | 1 |
| **Bmf** | 67 | 100 | NB | 16 | 254 | >2,000 | >1,000 | 300 | 3 | 9.8 | 9.7 | 1,100 | 180 |
| **Bik** | 26 | 5 | 250 | 140 | 10 | 6 | 18 | 29 | 131 | 2.6 | 4.3 | 4.6 | 2.4 | 1 |
| **Bax** | 46 | 50 | 3,400 | 6,930 | 76 | 29 | 150 | <50 | 690 | 100 | 58 | 130 | 12 | n/a |
| **Bak** | 32 | 75 | 1,850 | 4,040 | 76 | 26 | 1,400 | 980 | 690 | 100 | 58 | 130 | 12 | n/a |

*Affinity measured in nM by surface plasmon resonance (K_<sub>D</sub>).*

*Affinity measured in nM by isothermal calorimetry (K_<sub>D</sub>).*

*Affinity measured in nM by fluorescence polarization (IC<sub>50</sub>).*

The table shows the binding affinities of prosurvival Bcl-2 proteins to BH3 domain peptides of proapoptotic Bcl-2 proteins. The results are presented in terms of binding constants (K<sub>D</sub> or IC<sub>50</sub>) measured using various techniques. The table includes data for Poxviral Bcl-2 proteins from various viruses and for cellular Bcl-2 proteins Bcl-2, Bcl-<sub>2</sub>-w, Bcl-x<sub>L</sub>, and A1. The data indicate the relative affinity of each protein pair, with lower values indicating stronger binding.

Crystal structures of FPV039 with Bmf and Bik

![Crystal structures of FPV039 with Bmf and Bik](image)
shown for Epstein-Barr virus BHRF1 (30, 48). In comparison with mammalian Bcl-2 proteins, vBcl-2 proteins typically interact with host proapoptotic proteins with considerably lower affinity (7) and tend to target only a smaller subset of proapoptotic regulators. Certain vBcl-2 members such as vaccinia and variola virus F1L (18, 23) and deerpox virus DPV022 (21) target only a very restricted subset of host proapoptotic proteins, whereas others are more promiscuous such as sheeppox virus SPPV14 (19) and murine γ-herpesvirus 68 M11 (49). Interestingly, FPV039 is only the second vBcl-2 proteins after A179L (33) that has been shown to interact with all major host proapoptotic Bcl-2 proteins. Furthermore, FPV039 engages host BH3-only proteins with high affinities, thus more closely resembling the behavior of cellular prosurvival Bcl-2 rather than other vBcl-2 members. We note that the affinity of FPV039 for Bak is lower compared with cellular Bcl-2 proteins; however, the relative importance of all the proapoptotic ligands identified for FPV039 remains to be clarified. Nonetheless, this remarkable promiscuity is in striking contrast to vaccinia virus F1L (22), which relies solely on the sequestration of Bim to prevent host cell apoptosis, underscoring the diversity of mechanisms utilized by viruses and their Bcl-2 homologs to subvert intrinsic apoptosis.

Interestingly, FPV039 is one of a small number of vBcl-2 proteins that is able to engage Bad BH3, albeit with modest affinity (Table 3). This raises the prospect of targeting FPV039 with first-generation BH3 mimetics such as ABT-737 and ABT-263, which were designed as Bad BH3 mimetics and engage the same mammalian prosurvival Bcl-2 proteins as Bad (50). Although the utility of targeting vBcl-2 proteins for therapy remains to be established for the Poxviridae, the efficacy of such a strategy was recently demonstrated for Epstein-Barr virus BHRF1 (51).

A phylogenetic analysis of FPV039 and its homologs among the avipoxviruses reveals that they can be divided into two clades (Fig. 6A) in agreement with previous analyses using the conserved core 4b protein (52) and more recently DNA polymerase (53). Furthermore, the overall protein sequence conser-
vation between the canarypox and fowlpox Bcl-2 homologs is lower at 39% compared with overall conservation across homologous proteins (53%) (36), suggesting that the vBcl-2 proteins are subject to higher evolutionary pressure. This view would be consistent with the role of FPV039 as an immune evasion protein that is subject to higher selective pressure as part of the host-pathogen interface. Interestingly, mapping of conserved residues within the hydrophobic binding groove of FPV039 on avipoxviral homologs such as CNP058 reveals that several key residues in the groove are not conserved in the Clade B virus canarypox virus and even in the proximal Clade A virus turkeypox virus (Fig. 6B), suggesting that CNP058 is likely to harbor a different proapoptotic Bcl-2 ligand-binding profile compared with FPV039. Expansion of the phylogenetic analysis to include chicken prosurvival proteins reveals that the closest chicken prosurvival Bcl-2 protein is Mcl-1 (Fig. 6A). This finding is consistent with our identification of Mcl-1 as the closest structural homolog of FPV039 and the conservation of interactions between FPV039 and Mcl-1/BH3 ligand complexes. Consequently, it is tempting to speculate that chicken Mcl-1 may have been the first prosurvival Bcl-2 protein to be acquired by an ancestral avipoxvirus. However, this hypothesis requires experimental verification.

In summary, our findings reveal that FPV039 adopts a Bcl-2 fold similar to the mammalian prosurvival protein Mcl-1, which allows engagement of all BH3-only proteins as well as Bak and Bax with high affinity. Our results will allow a detailed dissection of the interactions between FPV039 and host proapoptotic regulators to establish whether or not all of them are required as well as to pinpoint which interactions are ultimately key for suppression of premature host cell apoptosis.

**Experimental procedures**

**FPV039 expression and purification**

Synthetic codon-optimized cDNA encoding for FPV039 lacking the C-terminal transmembrane domain (residues 1–143) (Genscript) was cloned into the bacterial expression vector pGEX6P-1 (GE Healthcare). The plasmid was transformed into *E. coli* BL21 Codon Plus cells and grown in 2YT (yeast/tryptone) medium supplemented with 1 mg/ml ampicillin at 37 °C in an incubator shaking at 180 rpm until the culture reached an *A*₅₆₂₀ of 0.6. Protein expression was induced using 0.5 mM isopropyl β-D-1-thiogalactopyranoside at 22 °C for 16 h. The cells were harvested by centrifugation at 3400 × *g* (JLA 9.1000 rotor, Beckman Coulter Avanti J-E) for 15 min, resuspended in 100 ml of lysis buffer (20 mM trisodium citrate, pH 6.0, 200 mM NaCl), and lysed using a sonicator at 50 kHz for four cycles (15 s) with 30-s rest intervals in the presence of lysozyme (Sigma-Aldrich) and DNase I (deoxyribonuclease I from bovine pancreas, Sigma-Aldrich). The resulting lysate was clarified by centrifugation at 31,000 × *g* (JA 25.50 rotor, Beckman Coulter Avanti J-E) for 30 min. The supernatant was filtered with a 0.45-μm filter (Millipore), loaded onto 5 ml of glutathione-Sepharose 4B beads (GE Healthcare) equilibrated with lysis buffer, and subsequently washed with 30 ml of lysis buffer. Human rhinovirus 3C protease was added to the column and incubated overnight at 4 °C to liberate the target protein from the GST affinity tag. The cleaved target protein was eluted and concentrated to 5 ml prior to being subjected to size-exclusion chromatography using a Superdex S75 16/600 column attached to an AKTAxpress system (GE Healthcare) equilibrated in 20 mM trisodium citrate, pH 6.0, 200 mM NaCl. The protein eluted as a single peak and displayed higher than 95% purity based on SDS-PAGE analysis.

**Measurement of interactions with BH3 peptides**

Affinities of FPV039 for different BH3 peptides were measured using a MicroCal iTC200 system (GE Healthcare) at 25 °C. The measurements were performed in 20 mM trisodium citrate, pH 6.0, 200 mM NaCl at a final protein concentration of 30 μM. BH3 domain peptides at concentration of 300 μM were titrated into the protein sample using 19 injections of 2 μl/injection. All assays were performed in triplicates. Protein concentrations were measured using a UV spectrophotometer (Thermo Scientific) at a wavelength of 280 nm. BH3 peptides concentrations were calculated from the dry weight of peptide. The BH3 peptides sequences used in this study are as follows: 1) *Gallus gallus* GG_Bak (UniProt accession number Q5F404), 2) *Homo sapiens* HS_Bak (UniProt accession number Q70812), 3) *Gallus gallus* GG_Bm (UniProt accession number A9XR9G), 4) *Homo sapiens* HS_Bid (UniProt accession number Q81GM8), 5) *Gallus gallus* GG_Bak (UniProt accession number Q91I82), 6) *Homo sapiens* HS_Bid (UniProt accession number Q92934-1), 7) *Gallus gallus* GG_Bak (UniProt accession number Q92934-1), 8) *Gallus gallus* GG_Bm (UniProt accession number Q81GM8), 9) *Homo sapiens* HS_Bid (UniProt accession number Q91I82), 10) *Gallus gallus* GG_Bak (UniProt accession number Q92934-1), 11) *Gallus gallus* GG_Bm (UniProt accession number Q81GM8), 12) *Homo sapiens* HS_Bak (UniProt accession number Q70812), 13) *Gallus gallus* GG_Bak (UniProt accession number Q92934-1), 14) *Homo sapiens* HS_Bak (UniProt accession number Q70812), 15) *Homo sapiens* HS_Bid (UniProt accession number Q92934-1), 16) *Gallus gallus* GG_Bak (UniProt accession number Q92934-1), 17) *Gallus gallus* GG_Bm (UniProt accession number Q81GM8), 18) *Homo sapiens* HS_Bid (UniProt accession number Q92934-1), 19) *Gallus gallus* GG_Bak (UniProt accession number Q92934-1), 20) *Gallus gallus* GG_Bm (UniProt accession number Q81GM8).

**Small angle X-ray scattering**

SAXS data were collected at the Australian Synchrotron SAXS/WAXS beamline using protocols described previously (21, 54). Briefly, FPV039 in complex with Bak BH3 at concentrations of 7.35, 3.34, 1.56, 0.70, and 0.31 mg/ml in 20 mM trisodium citrate, pH 6.0, 200 mM NaCl was measured in a q range between 0.025 and 0.6 Å⁻¹ at 12 keV with a 1.6-m camera length at 20 °C and collected on a Pilatus 1M detector (Dectris). The extinction coefficient of the complex was 1.872. Beam stop integration was used to achieve normalization. The data were absolute scaled using distilled water. The samples were measured in a 1.5-mm quartz capillary to minimize radiation damage and flowed past the beam while 30 × 1-s exposures were measured on samples and blanks. Software specific to the beamline was used to integrate, average, and calibrate the scattering images against water (55). The forward scattering (I(0)) and radius of gyration (Rₓ) were determined by the Guinier approximation (56, 57). Sample homogeneity and monodisper-
Crystal structures of FPV039 with Bmf and Bik

Complexes of FPV039 with Bik BH3 and Bmf BH3 were prepared as described previously (58). Briefly, FPV039 complexes were reconstituted by adding GG_Bik BH3 domain or GG_Bmf BH3 domain peptides at a 1:1:25 molar ratio to FPV039. The reconstituted complexes were concentrated to 10 mg/ml using a 3-kDa-molecular-mass-cutoff centrifugal concentrator (Millipore), flash cooled, and stored under liquid nitrogen. Crystallization trials were carried out using 96-well sitting-drop tray (Swissci) vapor diffusion at 20°C either in-house or at the Commonwealth Scientific and Industrial Research Organisation (CSIRO) C3 Collaborative Crystallization Centre, Melbourne, Australia. 0.15 μl of FPV039-BH3 domain peptide complex was mixed with 0.15 μl of various crystallization condition solutions using a Phoenix nanodispenser robot (Art Robbins). Commercially available screening kits (Crystal Screen, PACT Suite, JCSG-plus Screen, PEG/Ion Screen, and Shot-Gun Screen) were used for the initial crystallization screening with hit optimization performed either in-house using 24-well hanging-drop plates (EasyXtal DG-Tool, Qiagen) of 1 μl protein mixture with 1 μl of reservoir solution or using a 96-well plate at the CSIRO C3 Collaborative Crystallization Centre.

Crystals of FPV039 in complex with the Bmf BH3 domain were obtained at 10 mg/ml in three conditions: 1) 0.1 M MMT (DL-malic acid, MES and Tris), pH 8.0, 25% PEG 1500; 2) 0.2 M sodium formate, pH 7.2, 20% PEG 3350; and 3) 0.2 M lithium chloride, 20% PEG 3350, pH 6.8. All three conditions produced hexagonal crystals of FPV039-BH3 domain complex belonging to space group C2 in the monoclinic crystal system. The final crystal contained two molecules of FPV039, each bound to one molecule of Bmf BH3 in the asymmetric unit, and had a solvent content of 41.9%. The crystals were cryoprotected using 20% (v/v) ethylene glycol and flash cooled at 100 K using liquid nitrogen. All diffraction data were collected on the MX2 beamline at the Australian Synchrotron using an ADSC Quantum 315r charge-coupled device detector (Area Detector Systems Corp., Poway, CA) with an oscillation range of 1.0°/frame using a wavelength of 0.9537 Å. Diffraction data were integrated using XDS (59) and scaled using AIMLESS (60, 61). The structure was solved by molecular replacement with Phaser (62) using the previously determined structure of FPV039 as a search model (TFZ = 62.1 and LLG = 3342). The structure was built and refined using Coot and PHENIX, respectively. Data collection and refinement statistics details are summarized in Table 2. Coordinate files have been deposited in the Protein Data Bank under the accession codes 5TZQ and 5TZP. All images were generated using the PyMOL Molecular Graphics System, version 1.8 (Schrödinger, LLC). All software was accessed using the SBGrid suite (66). All raw diffraction images were deposited on the SBGrid Data Bank (67) using accession numbers doi 10.15785/SBGRID/443 and 10.15785/SBGRID/442.

Phylogenetic analysis

Protein sequences of avipoxvirus Bcl-2-like proteins (fowlpox, canarypox, turkeypox, penguinpox, and pigeonpox) and cellular Bcl-2 proteins including Mcl-1, Bcl-2, A1, Bcl-xL, and Bcl-w from human, mouse, chicken, turkey, and penguin were aligned using T-Coffee (68). The multiple sequence alignment was modified using Gblocks where Gblocks selects conserved blocks of sequences that lack poorly aligned positions and divergent regions (69). Due to highly divergent sequences in the analysis, a less stringent setting that allows smaller final blocks chosen by Gblocks was used. The phylogenetic tree was generated using a maximum likelihood (ML) approach using the maximum likelihood (PhyML) program (70, 71). The ML analysis was bootstrapped with 100 replicates. The final representation of the tree was produced using the tree dynamics (TreeDyn) program (72). T-Coffee, Gblocks, PhyML, and TreeDyn were accessed via the phylogeny.fr (73). The accession numbers for the sequences used in the phylogenetic analysis are as follows: 1) fowlpox FPV039, Q9J5G4; 2) pigeonpox Bcl-2, A0A068EE18; 3) penguinpox Bcl-2, A0A068EE4H; 4) turkeypox Bcl-2, A0A0M3JZJ2; 5) canarypox CNP058, Q6VZT9; 6) human Mcl-1, Q07820; 7) mouse Mcl-1, P97287; 8) chicken Mcl-1, Q9W6F1; 9) penguin Mcl-1, A0A087RIT1; 10) human Bcl-w, Q92843; 11) mouse Bcl-w, P70345; 12) chicken A1, Q9W6F2; 13) turkey A1, A0A091LE25; 14) penguin A1, A0A093PIE7; 15) human A1, Q16548; 16) mouse A1, Q07440; 17) human Bcl-xL, Q07817; 18) chicken Bcl-xL, Q07816; 19) turkey Bcl-xL, Q07816; 20) chicken Bcl-2, Q00709; 21) mouse Bcl-2, P10417; 22) human Bcl-2, P10415; and 23) penguin Bcl-2, A0A093NW22.

Acknowledgments—We thank staff at the MX and SAXS/WAXS beamlines at the Australian Synchrotron for help with X-ray data collection, the CSIRO C3 Collaborative Crystallization Centre for assistance with crystallization, and the Comprehensive Proteomics Platform at La Trobe University for core instrument support.
Crystal structures of FPV039 with Bmf and Bik

References

1. Kerr, J. F., Wyllie, A. H., and Currie, A. R. (1972) Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. *Br. J. Cancer* **26**, 239–257.
2. Youle, R. J., and Strasser, A. (2008) The BCL-2 protein family: opposing activities that mediate cell death. *Nat. Rev. Mol. Cell Biol.* **9**, 47–59.
3. Vaux, D. L., Haecker, G., and Strasser, A. (1994) An evolutionary perspective on apoptosis. *Cell* **76**, 777–779.
4. Green, D. R., and Kroemer, G. (2004) The pathophysiology of mitochondrial cell death. *Science* **305**, 626–629.
5. Galluzzi, L., Brenner, C., Morselli, E., Touat, Z., and Kroemer, G. (2008) Viral control of mitochondrial apoptosis. *PLoS Pathog.* **4**, e1000118.
6. Chijiu, J. E., Moldoveanu, T., Llambi, F., Parsons, M. I., and Green, D. R. (2010) The BCL-2 family reunion. *Mol. Cell. 37*, 299–310.
7. Kvansakul, M., and Hinds, M. G. (2013) Structural biology of the Bcl-2 family and its mimicry by viral proteins. *Cell Death Differ.* **21**, 196–205.
8. Westphal, D., Kluck, R. M., and Dewson, G. (2014) Building blocks of the apoptotic pore: how Bax and Bak are activated and oligomerize during apoptosis. *Cell Death Differ.* **21**, 508–520.
9. Shamas-Din, A., Brahmbhatt, H., Leber, B., and Andrews, D. W. (2011) BH3-only proteins: orchestrators of apoptosis. *Biochim. Biophys. Acta* **1813**, 508–520.
10. Henderson, S., Huen, D., Rowe, M., Dawson, C., Johnson, G., and Rickinson, A. (1993) Epstein-Barr virus-coded BHRF1 protein, a viral homolog of Bcl-2, protects human B cells from programmed cell death. *Proc. Natl. Acad. Sci. U.S.A.* **90**, 6479–6483.
11. Banaduya, L., Veugelers, K., Campbell, S., and Barry, M. (2009) The fowlpox virus BCL-2 homologue, FPV039, interacts with activated Bax and a discrete subset of BH3-only proteins to inhibit apoptosis. *J. Virol.* **83**, 7085–7098.
12. Raulet, D. H., Youle, R. J. (1997) Nonionic detergents induce dimerization of the Bcl-2-like anti-apoptotic protein. *Proc. Natl. Acad. Sci. U.S.A.* **94**, 690–694.
13. Wilson-Annan, J., O’Reilly, L. A., Crawford, S. A., Hausmann, G., Beauvillain, A., van Boe/Diva reveals a divergent Bcl-2-like protein. *J. Virol.* **81**, 2583–2588.
Crystal structures of FPV039 with Bmf and Bik

43. Shamas-Din, A., Kale, J., Leber, B., and Andrews, D. W. (2013) Mechanisms of action of Bcl-2 family proteins. *Cold Spring Harb. Perspect. Biol.* 5, a008714

44. Westphal, D., Ledgerwood, E. C., Tyndall, J. D., Hibma, M. H., Ueda, N., Fleming, S. B., and Mercer, A. A. (2009) The orphan virus inhibitor of apoptosis functions in a Bcl-2-like manner, binding and neutralizing a set of BH3-only proteins and active Bax. *Apoptosis* 14, 1317–1330

45. Kirby, N. M., and Leaman, D. W. (2015) Involvement of Noxa in cellular apoptotic responses to interferon, double-stranded RNA, and virus infection. *J. Biol. Chem.* 280, 15561–15568

46. Eitz Ferrer, P., Potthoff, S., Kirschnek, S., Gasteiger, G., Kastenmüller, W., Sun, Y., and Leaman, D. W. (2005) Involvement of Noxa in cellular apoptosis regulation. *J. Biol. Chem.* 280, 6563–6568

47. Procko, E., Berguig, G. Y., Shen, B. W., Song, Y., Frayo, S., Convertine, A. J., Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Kappler, J. W., and Marrack, P. (2009) The Epstein-Barr virus Bcl-2 homolog, BHRF1, blocks apoptosis by binding to a limited amount of Bim. *Proc. Natl. Acad. Sci. U.S.A.* 106, 5663–5668

48. Ku, B., Woo, J. S., Liang, C., Lee, K. H., Hong, H. S., P. E. X., Kim, S. M., Jung, J. U., and Oh, B. H. (2008) Structural and biochemical bases for the inhibition of autophagy and apoptosis by viral BCL-2 of murine γ-herpesvirus 68. *PLoS Pathog.* 4, e25

49. Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Beli, B. A., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., Joseph, M. K., Kitada, S., Korsmeyer, S. J., and Adams, P. D. (2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours. *Nature* 435, 677–681

50. Procko, E., Berguig, G. Y., Shen, B. W., Song, Y., Frayo, S., Convertine, A. J., Margineantu, D., Booth, G., Correa, B. E., Cheng, Y., Schief, W. R., Hockenbery, D. M., Press, O. W., Stoddard, B. L., Stayton, P. S., et al. (2014) A computationally designed inhibitor of an Epstein-Barr viral Bcl-2 protein induces apoptosis in infected cells. *Cell* 157, 1644–1656

51. Jarmin, S., Manvell, R., Gough, R. E., Laidlaw, S. M., and Skinner, M. A. (2006) Avipoxvirus phylogenetics: identification of a PCR length polymorphism that discriminates between the two major clades. *J. Gen. Virol.* 87, 2191–2201

52. Gyurazencz, M., Foster, J. T., Dán, Á., Ip, H. S., Egstad, K. F., Parker, P. G., Sósk, E., Kim, Y. J., Uhart, M., Castresana, J., et al. (2013) Worldwide phylogenetic relationship of avian poxviruses. *J. Virol.* 87, 4938–4951

53. Caria, S., Marshall, B., Burton, R. L., Campbell, S., Pantaki-Eimany, D., Hawkins, C. J., Barry, M., and Kvansakul, M. (2016) The N terminus of the vaccinia virus protein FIL is an intrinsically unstructured region that is not involved in apoptosis regulation. *J. Biol. Chem.* 291, 14600–14608

54. Kirby, N. M., and Cowieson, N. P. (2014) Time-resolved studies of dynamic biomolecules using small angle X-ray scattering. *Curr. Opin. Struct. Biol.* 28, 41–46

55. Petoukhov, M. V., Franke, D., Shkumatov, A. V., Triia, G., Kühnkey, A. G., Gajda, M., Gorba, C., Mertens, H. D., Konarev, P. V., and Svergun, D. I. (2012) New developments in the program package for small-angle scattering data analysis. *J. Appl. Crystallogr.* 45, 342–350

56. Konarev, P. V., Volkov, V. V., Sokolova, A. V., Koch, M. H., and Svergun, D. I. (2003) PRIMUS: a Windows PC-based system for small-angle scattering data analysis. *J. Appl. Crystallogr.* 36, 1277–1282

57. Kabsch, W. (2010) XDS. *Acta Crystallogr. D Biol. Crystallogr.* 66, 125–132

58. Evans, P. (2006) Scaling and assessment of data quality. *Acta Crystallogr. D Biol. Crystallogr.* 62, 72–82

59. Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Kleywegt, G. J., Krissinel, E. B., Leslie, A. G., McCoy, A., McNicholas, S. I., Murshudov, G. N., Pannu, N. S., Pötterton, E. A., Powell, H. R., et al. (2011) Overview of the CCP4 suite and current developments. *Acta Crystallogr. D Biol. Crystallogr.* 67, 235–242

60. McCoy, A. J. (2007) Solving structures of protein complexes by molecular replacement with Phaser. *Acta Crystallogr. D Biol. Crystallogr.* 63, 32–41

61. Anisimova, M., and Gascuel, O. (2006) Approximate likelihood-ratio test statistics for branches: a fast, accurate, and powerful alternative. *Syst. Biol.* 55, 539–552

62. Meyer, P. A., Socias, S., Key, J., Sanseglur, P. C., Timony, M. A., Ottaviano, M., and Sliz, P. (2013) Collaboration gets the most out of software. *Elife* 2, e01456

63. Castresana, J. (2000) Selection of conserved blocks from multiple alignments for their use in phylogenetic analysis. *Mol. Biol. Evol.* 17, 540–552

64. Anisimova, M., and Gascuel, O. (2006) Approximate likelihood-ratio test statistics for branches: a fast, accurate, and powerful alternative. *Syst. Biol.* 55, 539–552

65. Guindon, S., and Gascuel, O. (2003) A fast, accurate and powerful method for fast and accurate multiple sequence alignment. *Syst. Biol.* 52, 104–115

66. Dereeper, A., Guignon, V., Blanc, G., Audic, S., Dufayard, J. F., Guindon, S., Lefort, V., Claverie, J. M., and Dufayard, J. F. (2007) Phylogeny.fr: robust phylogenetic analysis for the non-specialist. *Nucleic Acids Res.* 35, 37–47

67. Dereeper, A., Guignon, V., Blanc, G., Audic, S., Dufayard, J. F., Guindon, S., Lefort, V., Claverie, J. M., and Gascuel, O. (2008) Phylogeny.fr: robust phylogenetic analysis for the non-specialist. *Nucleic Acids Res.* 36, W465–W469

68. Whitten, A. E., Cai, S., and Trewella, J. (2008) MULCh: modules for the analysis of small-angle neutron contrast variation data from biomolecular assemblies. *J. Appl. Crystallogr.* 41, 222–226